European Industrial Pharmacists Group

Best wishes to all EIPG members! 

🌟 𝐒𝐭𝐚𝐲 𝐀𝐡𝐞𝐚𝐝 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐄𝐈𝐏𝐆 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫!🌟   Discover the latest updates shaping the pharmaceutical and healthcare industries: ✅ 𝐄𝐔 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 – Insights from Mario Draghi's report. ✅ 𝐒𝐮𝐩𝐩𝐥𝐲 𝐂𝐡𝐚𝐢𝐧 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 – Understanding the impact of the CSDDD directive. ✅ 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧𝐬 – Highlights from the ACT-EU initiative. ✅ 𝐅𝐮𝐭𝐮𝐫𝐞 𝐑&𝐃 𝐃𝐢𝐫𝐞𝐜𝐭𝐢𝐨𝐧𝐬 – Post-2024 elections and upcoming Horizon Europe projects.   Exclusive for #EIPG members: 🎓 𝐒𝐩𝐞𝐜𝐢𝐚𝐥 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐬 𝐨𝐧 𝐭𝐫𝐚𝐢𝐧𝐢𝐧𝐠 modules about EU GMP Annex 1 compliance course! 📬 Don’t miss this 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 𝐭𝐨 𝐬𝐭𝐚𝐲 𝐢𝐧𝐟𝐨𝐫𝐦𝐞𝐝 and grow professionally. 📖 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐧𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫👇   #Pharma #HealthcareInnovation #ProfessionalDevelopment #RandD #ClinicalTrials

𝐀𝐜𝐚𝐝𝐞𝐦𝐢𝐜 𝐩𝐚𝐭𝐞𝐧𝐭𝐢𝐧𝐠 𝐨𝐧 𝐭𝐡𝐞 𝐫𝐢𝐬𝐞 The document explores the rise in academic patenting, highlighting the importance of basic research for technological breakthroughs like #mRNA vaccines. It discusses patent distribution among European universities, emphasising the dominance of larger institutions with Knowledge Transfer Offices. Additionally, it examines #legislative impacts and collaboration trends, underscoring the growing role of partnerships in intellectual property.

The medicine and biology sectors are the higher contributors to academic patenting, says a recent report from EPO on academic patenting #eipgeu #epo #patents #academia https://lnkd.in/dqFNGRYa

EIPG promoted two training sessions on November 14th and 21st, 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐨𝐧 𝐈𝐂𝐇 𝐐𝟗 (𝐑𝟏). Two highly knowledgeable speakers and ICH Q9 working group members led the sessions. The speakers explained the changes introduced in the new version of this 𝐟𝐮𝐧𝐝𝐚𝐦𝐞𝐧𝐭𝐚𝐥 𝐠𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞 clearly and detailed and shared application examples. Our heartfelt thanks go to Peer Schmidt and Michael Schousboe for their invaluable contribution to the professional development of industrial pharmacists, in line with the plan promoted by EIPG. #training #pharma

IFPMA published a statement summarising key factors for successful pharmaceutical technology transfers towards lower-income countries #eipgeu #PPTs #IFPMA #pharmaceuticaltechnologytransfers https://lnkd.in/di9v_HJH

After a long wait, the first revision of the ERA guideline on environmental risk assessment entered into force in September 2024. #eipgeu #era #environmentalriskassessment #ema #guideline https://lnkd.in/dKfFarjZ

𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐞𝐐𝐌𝐒 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 | 𝐓𝐡𝐞 𝐄𝐟𝐟𝐞𝐜𝐭 𝐨𝐟 𝐃𝐢𝐠𝐢𝐭𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 As digital transformation accelerates across industries, the 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐬𝐞𝐜𝐭𝐨𝐫 is also embracing digital solutions to enhance 𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐬𝐲𝐬𝐭𝐞𝐦𝐬 (eQMS). The webinar organized by MakingLife, which features Piero Iamartino, moderator of the event, Fabio Geremia, Luca Sala and Peter De Brabandere, Ceo of Bizzmine, explores how 𝐝𝐢𝐠𝐢𝐭𝐚𝐥𝐢𝐬𝐚𝐭𝐢𝐨𝐧 𝐢𝐬 𝐫𝐞𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐞𝐐𝐌𝐒, bringing operational efficiency, accuracy of data and increased compliance at the forefront of the pharmaceutical industry. 📍 SAVE THE DATE 📅 29th November 2024 | h. 12-1pm 🔍 The round table will try to analyze the aspects linked to the 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 𝐨𝐟 𝐝𝐢𝐠𝐢𝐭𝐚𝐥𝐢𝐬𝐚𝐭𝐢𝐨𝐧, focusing on the need to equip your company with a digital eQMS for staying competitive and compliant in a fast-evolving market. For more details and to register for the webinar 👇

Calling EIPG members. Annex 2 of ICH GCP now out for consultation.

European authorities have issued an updated 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐟𝐨𝐫 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐝𝐫𝐮𝐠𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐄𝐔, citing recent advances in manufacturing technologies and new global challenges as drivers of the revision.   The updated strategy -#EMANS28- was issued for consultation by the EMA and the Heads of Medicines Agencies (#HMA) on October 3. 👉 https://lnkd.in/e-p7FyaG   EIPG will participate in this consultation, which will focus on the following strategic areas: 𝐚𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐭𝐨 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬, 𝐝𝐢𝐠𝐢𝐭𝐚𝐥𝐢𝐬𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐀.𝐈., 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲, 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬, 𝐚𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞, 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐬𝐮𝐩𝐩𝐥𝐲, 𝐚𝐧𝐝 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐧𝐞𝐭𝐰𝐨𝐫𝐤. #regulatory #EMA